In contrast, neither the SW48-G13D nor SW48-G12V xenograft model was sensitive to ixazomib (T/C = 1.05 and 0.99), suggesting that introduction of a KRAS mutation is sufficient to drive resistance to PI in tumor xenograft models in vivo. The gene discussed is KRAS; the disease is neoplasm.